Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Melanoma genetics and the development of rational therapeutics
Yakov Chudnovsky, … , Paul A. Khavari, Amy E. Adams
Yakov Chudnovsky, … , Paul A. Khavari, Amy E. Adams
Published April 1, 2005
Citation Information: J Clin Invest. 2005;115(4):813-824. https://doi.org/10.1172/JCI24808.
View: Text | PDF
Science in Medicine

Melanoma genetics and the development of rational therapeutics

  • Text
  • PDF
Abstract

Melanoma is a cancer of the neural crest–derived cells that provide pigmentation to skin and other tissues. Over the past 4 decades, the incidence of melanoma has increased more rapidly than that of any other malignancy in the United States. No current treatments substantially enhance patient survival once metastasis has occurred. This review focuses on recent insights into melanoma genetics and new therapeutic approaches being developed based on these advances.

Authors

Yakov Chudnovsky, Paul A. Khavari, Amy E. Adams

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Genetic encoding and mechanism of action of tumor suppressors p16INK4a a...
Genetic encoding and mechanism of action of tumor suppressors p16INK4a and p14ARF. The CDKN2A locus on chromosome 9p21 is composed of 4 exons (E) – 1α, 1β, 2, and 3 – and encodes 2 tumor suppressors, p16INK4a and p14ARF (termed p19ARF in the mouse), via alternative reading frames. p16INK4a is translated from the splice product of E1α, E2, and E3, while p14ARF is translated from the splice product of E1β, E2, and E3. Normally p16INK4a sequesters CDK4 and CDK6 thereby keeping pRb in an active hypophosphorylated state. In the absence of p16INK4a, CDK4 and CDK6 bind cyclin D and phosphorylate Rb. Phosphorylated pRb then releases the E2F transcription factor, which promotes the G1-to-S phase transition of the cell cycle. p14ARF, on the other hand, sequesters the p53-specific ubiquitin ligase HDM2. In the absence of p14ARF, HDM2 targets p53 for ubiquitination (UUU) and subsequent proteosomal degradation, and the loss of p53 impairs mechanisms that normally target genetically damaged cells for cell cycle arrest and/or apoptosis, which leads to proliferation of damaged cells. Loss of CDKN2A therefore contributes to tumorigenesis by disruption of both the pRb and p53 pathways. Figure modified with permission from N. Engl. J. Med. (S30).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts